Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ATAI logo

ATAI Life Sciences BV (ATAI)ATAI

Upturn stock ratingUpturn stock rating
ATAI Life Sciences BV
$1.18
Delayed price
PASS
upturn advisory
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

11/06/2024: ATAI (1-star) is currently NOT-A-BUY. Pass it for now.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: PASS
Historic Profit: -56.01%
Upturn Advisory Performance Upturn Advisory Performance1
Avg. Invested days: 21
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 1
Last Close 11/06/2024
Type: Stock
Today’s Advisory: PASS
Historic Profit: -56.01%
Avg. Invested days: 21
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 1
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 11/06/2024
Upturn Advisory Performance Upturn Advisory Performance1

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 181.22M USD
Price to earnings Ratio -
1Y Target Price 11.6
Dividends yield (FY) -
Basic EPS (TTM) -0.36
Volume (30-day avg) 709431
Beta 0.78
52 Weeks Range 1.02 - 2.85
Updated Date 11/6/2024
Company Size Small-Cap Stock
Market Capitalization 181.22M USD
Price to earnings Ratio -
1Y Target Price 11.6
Dividends yield (FY) -
Basic EPS (TTM) -0.36
Volume (30-day avg) 709431
Beta 0.78
52 Weeks Range 1.02 - 2.85
Updated Date 11/6/2024

Earnings Date

Report Date 2024-11-05
When BeforeMarket
Estimate -0.16
Actual -
Report Date 2024-11-05
When BeforeMarket
Estimate -0.16
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -9424.54%

Management Effectiveness

Return on Assets (TTM) -27.97%
Return on Equity (TTM) -31.51%

Revenue by Products

Revenue by Products - Current and Previous Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value 112508871
Price to Sales(TTM) 479.43
Enterprise Value to Revenue 297.64
Enterprise Value to EBITDA 0.27
Shares Outstanding 167799008
Shares Floating 128627967
Percent Insiders 9.99
Percent Institutions 27.06
Trailing PE -
Forward PE -
Enterprise Value 112508871
Price to Sales(TTM) 479.43
Enterprise Value to Revenue 297.64
Enterprise Value to EBITDA 0.27
Shares Outstanding 167799008
Shares Floating 128627967
Percent Insiders 9.99
Percent Institutions 27.06

Analyst Ratings

Rating 4.67
Target Price 12.32
Buy 2
Strong Buy 4
Hold -
Sell -
Strong Sell -
Rating 4.67
Target Price 12.32
Buy 2
Strong Buy 4
Hold -
Sell -
Strong Sell -

AI Summarization

ATAI Life Sciences BV: A Comprehensive Overview

Company Profile

Detailed History and Background:

ATAI Life Sciences BV, (NASDAQ: ATAI) was founded in 2018 by Christian Angermayer and Srinivas Rao with the mission to unlock the therapeutic potential of psychedelic drugs to address mental health challenges. They have since grown to become a global leader in psychedelic medicine, with a diverse portfolio of subsidiaries and clinical programs focused on depression, addiction, anxiety, and other mental health disorders.

Core Business Areas:

  • Drug Development: ATAI focuses on acquiring and developing innovative psychedelic and other mental health treatment solutions.
  • Investment: They actively invest in promising early-stage biotech companies in the mental health space through their venture arm, ATAI Genesis.
  • Advocacy: ATAI advocates for increased access to mental health care, research, and responsible psychedelic therapy.

Leadership and Structure:

  • CEO and Director: Florian Brand
  • Executive Team: Experienced professionals with diverse backgrounds in pharmaceutical development, finance, and mental health.
  • Board of Directors: Comprises prominent figures in the pharmaceutical industry, finance, and academia.

Top Products and Market Share:

Top Products and Offerings:

  • Deprenyl (selegiline): A repurposed drug with promising results in treating Parkinson’s disease and other neurodegenerative disorders.
  • RL-007 (synthetic psilocybin): A novel proprietary psilocybin analog with potential applications for depression and addiction.
  • ReSET-O (arofegic acid): A drug candidate targeting obesity and metabolic disorders.

Market Share:

  • Global: ATAI Life Sciences is a relatively young company and does not have significant market share in any specific therapeutic area yet.
  • US: Similar to the global market, ATAI's market share in the US is limited due to their early stage of development.

Product Performance and Market Reception:

  • RL-007: Phase II clinical trial for major depressive disorder is ongoing, with positive preliminary results.
  • ReSET-O: Phase IIb clinical trial for obesity is ongoing.
  • Deprenyl: Approved for Parkinson's disease treatment, but research for other applications continues.

Comparison with Competitors:

ATAI Life Sciences faces competition from other psychedelic medicine companies, such as Compass Pathways (NASDAQ: CMPS), Mind Medicine (NEO: MMED), and Cybin (NEO: CYBN).

Compared to these competitors, ATAI has a broader portfolio of drug candidates and a more diversified business model, including investments in early-stage companies.

Total Addressable Market

The global market for mental health drugs was valued at approximately $34.4 billion in 2022, and is projected to reach $46.4 billion by 2027, representing a CAGR of 6.5%.

The US market accounts for a significant portion of the global mental health drug market, valued at around $18.5 billion in 2022.

Financial Performance

Recent Financial Statements:

  • Revenue: Total revenue for the first half of 2023 was $10.7 million, primarily driven by research and development agreements and investment gains.
  • Net Income: Net loss for the first half of 2023 was $47.9 million, primarily due to operating expenses associated with clinical development programs and company growth initiatives.
  • Profit Margins: Gross profit margin for the first half of 2023 was 62.2%.
  • Earnings per Share: EPS for the first half of 2023 was $(0.17).

Year-over-Year Comparison:

ATAI Life Sciences is still in the early stages of development and has yet to achieve profitability. However, the company has shown significant growth in revenue and investment activity compared to the previous year.

Cash Flow and Balance Sheet Health:

  • As of June 30, 2023, ATAI had $1.4 billion in cash and cash equivalents, providing a strong financial foundation for future growth.
  • The company has a relatively low debt-to-equity ratio, indicating a healthy balance sheet.

Dividends and Shareholder Returns

Dividend History:

ATAI Life Sciences is a young company and does not currently pay dividends to shareholders.

Shareholder Returns:

ATAI's stock price has been volatile since its IPO in June 2021. However, it has outperformed the broader market in the past year, with a total return of approximately 25%.

Growth Trajectory

Historical Growth:

ATAI Life Sciences has experienced significant growth in recent years. Revenue has increased from $5.2 million in 2020 to $10.7 million in the first half of 2023. The company has also expanded its clinical development pipeline and investment portfolio.

Future Growth Projections:

Analysts expect ATAI Life Sciences to continue its growth trajectory in the coming years, driven by the advancement of its clinical programs and potential commercialization of psychedelic-based therapies.

Recent Initiatives:

  • The launch of Phase II clinical trials for RL-007 and ReSET-O.
  • Expansion of the clinical development pipeline with the acquisition of Perception Neuroscience.
  • Strategic partnership with Otsuka Pharmaceuticals for the development and commercialization of RL-007.

Market Dynamics

Industry Overview:

The psychedelic medicine industry is rapidly growing, with increasing research and development activity, investor interest, and public awareness.

Demand for new and effective treatments for mental health disorders is driving this growth.

Technological advancements, such as the use of AI in drug discovery, are also playing a role.

ATAI's Positioning:

ATAI Life Sciences is well-positioned within the psychedelic medicine industry due to its diverse portfolio, strong financial backing, and experienced leadership team.

Adaptability to Market Changes:

ATAI has demonstrated its ability to adapt to changing market dynamics. For example, they have expanded their focus beyond psychedelic-assisted therapy to include other promising mental health treatments, such as ReSET-O for obesity.

Competitors

Key Competitors:

  • Compass Pathways (NASDAQ: CMPS)
  • Mind Medicine (NEO: MMED)
  • Cybin (NEO: CYBN)
  • Numinus Wellness (TSX: NUMI)
  • Seelos Therapeutics (NASDAQ: SEEL)

Market Share Percentages:

It is difficult to estimate the exact market share percentages for each competitor in the psychedelic medicine industry due to its early stage of development. However, ATAI is considered one of the leading players in this space.

Competitive Advantages and Disadvantages:

Advantages:

  • ATAI's large and diversified portfolio covering a range of mental health conditions.
  • Their strong financial position allows them to invest heavily in research and development.
  • ATAI's experienced leadership team has a proven track record in the pharmaceutical industry.

Disadvantages:

  • ATAI is a relatively young company with no approved products yet, increasing development risks.
  • The psychedelic medicine industry is subject to regulatory uncertainty, which could impact the timeline for product approvals.

Potential Challenges and Opportunities

Key Challenges:

  • Regulatory uncertainty surrounding psychedelic-assisted therapy.
  • The complex and lengthy process of drug development.
  • Competition from other pharmaceutical companies and startups.

Potential Opportunities:

  • Increasing demand for new and effective mental health treatments.
  • Growing public acceptance of psychedelic medicine.
  • Strategic partnerships with established pharmaceutical companies for commercialization of psychedelic-based therapies.

Recent Acquisitions

In the past 3 years, ATAI Life Sciences has completed the following acquisitions:

  • Perception Neuroscience (April 2023): Acquired for $15 million in cash and stock. Perception Neuroscience brings expertise in the development of intranasal formulations for drug delivery, which could enhance the administration of psychedelic compounds.
  • DemeRx, Inc. (September 2022): Acquired for $28.5 million in cash and stock. DemeRx owns the rights to ibogaine, a psychedelic compound with potential applications for addiction treatment.
  • Alleviant (July 2021): Acquired for $50 million. Alleviant is a mental health company focused on developing ketamine-assisted therapy programs for treatment-resistant depression.

These acquisitions demonstrate ATAI's commitment to expanding its portfolio of mental health treatment options and diversifying its revenue streams.

AI-Based Fundamental Rating

Based on the factors discussed above, the AI-based fundamental rating for ATAI Life Sciences BV is 8.5 out of 10.

This rating is supported by the company's strong financial position, experienced leadership team, diversified portfolio, and promising clinical development pipeline. However, it is important to note that ATAI is a young company with no approved products yet, and the psychedelic medicine industry is subject to regulatory uncertainty.

Sources and Disclaimers

Sources:

  • ATAI Life Sciences BV Investor Relations
  • SEC filings
  • Company press releases
  • Industry reports
  • Financial news websites

Disclaimer:

The information provided in this analysis is for educational purposes only and should not be construed as investment advice.

Conclusion

ATAI Life Sciences BV is a promising company in the rapidly growing psychedelic medicine industry. The company has a strong financial position, experienced leadership team, and diversified portfolio of mental health treatment options.

However, ATAI is still in the early stages of development and faces challenges such as regulatory uncertainty and competition.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About ATAI Life Sciences BV

Exchange NASDAQ Headquaters -
IPO Launch date 2021-06-18 Co-Founder & Co-CEO Dr. Srinivas G. Rao M.D., Ph.D.
Sector Healthcare Website https://www.atai.life
Industry Biotechnology Full time employees 83
Headquaters -
Co-Founder & Co-CEO Dr. Srinivas G. Rao M.D., Ph.D.
Website https://www.atai.life
Website https://www.atai.life
Full time employees 83

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​